Hemobiotech, Inc. Information

HemoBioTech is engaged in the commercial development of HemoTech, a novel human blood substitute technology developed by Texas Tech University Health Sciences Center scientists, Drs. Mario Feola and Jan Simoni, and exclusively licensed from Texas Tech University System. HemoTech is composed of bovine hemoglobin that is chemically modified with ATP, Adenosine and GSH. HemoTech not only can carry oxygen in the blood, but can also induce erythropoiesis (red blood cell production). The Company believes that HemoTech, due to its novel structure, may possess properties that diminish the intrinsic toxicities that have plagued other attempts at developing blood substitutes, based upon pre-clinical and initial human clinical trials undertaken outside the U.S. HemoTech is being subjected to further studies and testing to confirm and expand on these studies. At a recent meeting in April, 2008 by the U.S. Food and Drug Administration (FDA) for blood substitutes, the FDA indicated the need for a new generation of hemoglobin based blood substitutes and the Adenosine-GSH approach of HemoTech was cited. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, as well as for other conditions. HemoBioTech received an exclusive worldwide license from the Texas Tech University System for a new technology that addresses the safety of animal-derived products for human use in pharmaceutical, cosmetic and other industries. This new technology, ORTH, acts to prevent the spread of transmissible spongiform encephalopathies (TSE), also know as prions which can cause disease such as mad cow disease, as well as viruses. The FDA strictly regulates medicinal products and cosmetics that contain ingredients from animals, particularly of bovine origin. The market for such pharmaceutical and cosmetic products for human use derived from animals is in excess of $7 billion. The technology is being used in the manufacturing of HemoBioTech's lead product HemoTech. The goal is to sublicense the ...